Next Tuesday, August 15, Bristol Myers Squibb is expected to seek an court order (known as a preliminary injunction) blocking Apotex from continuing to sell a generic version of its blockbuster anti-coagulant drug Plavix. A hearing on the motion may be held as early as Wednesday. Meanwhile the U.S. Department of Justice antitrust investigation of an aborted deal between the two companies continues.